by The global preeclampsia diagnostics market is one of the fastest growing segments in the healthcare sector, owing to rising incidences of preeclampsia among pregnant women globally. Preeclampsia is a pregnancy complication characterized by high blood pressure and signs of damage to another organ system. Advanced diagnostic tools for early detection and timely diagnosis of preeclampsia help reduce the risks associated with the condition and ensure better health outcomes for both mother and baby.
Preeclampsia affects 3–8% of all pregnancies worldwide and is a leading cause of maternal and fetal illness and death. Traditional diagnostic approaches for preeclampsia rely on measuring blood pressure and searching urine for protein, which do not always indicate the onset of the condition accurately. Advanced diagnostic tools analyze various biomarkers in blood and urine samples to detect even mild signs of preeclampsia at an early stage. This helps clinicians monitor at-risk patients more closely and initiate treatment before the condition progresses into a potentially life-threatening form. Furthermore, tools based on techniques like proteomics and metabolomics provide insights into disease pathogenesis and aid development of novel therapeutics and preventive strategies.
The global preeclampsia diagnostics market is estimated to be valued at US$ 347.2 million in 2023 and is expected to exhibit a CAGR of 4.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the Global preeclampsia diagnostics market size is the increasing adoption of biomarker-based diagnostic tests. Researchers have identified several novel biomarkers in body fluids that indicate onset of the condition in early stages of pregnancy, often before symptoms appear. This enables timely diagnosis and intervention. Major companies are focusing on developing advanced immunoassay kits and microfluidic-based platforms for rapid, accurate, and early detection of preeclampsia using biomarker protein profiles. This is expected to make routine biomarker screening a standard practice for at-risk pregnancies. The introduction of such cutting-edge solutions will help address the unmet needs in preeclampsia management over the forecast period.
Porter’s Analysis
Threat of new entrants: The preeclampsia diagnostics market requires high R&D investments and regulatory approvals which make it difficult for new players to enter the market.
Bargaining power of buyers: Buyers have moderate bargaining power as there are several vendors offering preeclampsia diagnostic tests.
Bargaining power of suppliers: Suppliers have low to moderate bargaining power owing to the availability of substitute raw materials.
Threat of new substitutes: Threat of substitutes is low as there are limited alternatives for preeclampsia diagnostics.
Competitive rivalry: The market is competitive with the presence of both international and regional players.
Key Takeaways
The global preeclampsia diagnostics market is expected to witness high growth over the forecast period. The global preeclampsia diagnostics market is estimated to be valued at US$ 347.2 million in 2023 and is expected to exhibit a CAGR of 4.5% over the forecast period 2023 to 2030.
Regional analysis: North America is anticipated to account for the largest share of the preeclampsia diagnostics market during the forecast period. This is attributed to the growing awareness regarding preeclampsia incountries like the US and Canada. The market in Asia Pacific is expected to grow at the highest CAGR during the forecast period due to the increasing healthcare expenditure and growing number of diagnostic laboratories in emerging countries of the region.
Key players: Key players operating in the preeclampsia diagnostics market are Siemens Healthineers, Roche Diagnostics, PerkinElmer Inc., Bayer Healthcare, DRG INSTRUMENTS GMBH, Metabolomic Diagnostics Ltd. and Abbott Laboratories. Key players are focusing on new product approvals and launches to expand their market presence.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
